Innovative medicines for transthyretin (TTR) rare diseases

Big Idea

BSIM Therapeutics is an academic spinoff founded in 2011 as a result of scientific research conducted at the University of Coimbra, in collaboration with the University of Leeds, in the United Kingdom. Its mission is to work every day to become a global reference in the discovery and development of innovative medicines for the treatment of rare neurodegenerative diseases, focusing particularly on transthyretin-mediated amyloidosis. It contributes to the health and well-being of all patients with ATTR, developing medicines for as yet untreated clinical manifestations, as well as alternative treatments that offer a better cost-benefit ratio compared to those already available on the market. The quality and validity of the strategy followed by BSIM Therapeutics has not only seen several applications submitted to Community funds (QREN and Portugal2020) approved, it has also attracted different investors, among which a venture capital firm, Portugal Ventures, a business angel, A2B SGPS, and a pharmaceutical company, Bluepharma.


Rui Brito – CEO; Carlos Simões – CTO.

Portugal Ventures Investment Manager

Patrícia Costa